Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 9
Submit an article Journal homepage
382
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Changing role of bone marrow examination in the diagnosis of hematological malignancies

Surender JunejaDepartment of Haematology, The Royal Melbourne Hospital, Melbourne, Australia; ;Peter MaCallum Cancer Centre, Melbourne, Australia; ;Department of Pathology, University of Melbourne, Melbourne, AustraliaCorrespondence[email protected]
&
David WestermanPeter MaCallum Cancer Centre, Melbourne, Australia; ;Department of Pathology, University of Melbourne, Melbourne, Australia
Pages 2018-2020 | Received 16 Jan 2018, Accepted 16 Jan 2018, Published online: 12 Feb 2018

References

  • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.
  • Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
  • Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC; 2008.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic & lymphoid tissues. Lyon (France): IARC; 2016.
  • Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
  • Oster HS, Carmi G, Kolomansky A, et al. Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. Leuk Lymphoma. 2018;2:1–6.
  • Tefferi A, Hanson CA, Ketterling RP. Revisiting the need for bone marrow examination in chronic myeloid leukemia. Am J Hematol. 2018;93:5–7.
  • Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–336.
  • Zhou Y, Wood BL, Walter RB, et al. Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed? Leukemia. 2017;31:2536–2537.
  • Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow is highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–2103.
  • Yeh P, Dickinson M, Ftouni S, et al. Molecular disease monitoring using circulating tumour DNA in myelodysplastic syndromes. Blood. 2017;129:1685–1690.
  • Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.